Amy K. Kim

Dr. Amy K. Kim

Department of Medicine Division of Gastroenterology/Hepatology, Johns Hopkins School of Medicine, Baltimore, MD, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ZFZachariah H. Foda
Zachariah H. Foda
AAAkshaya V. Annapragada
Akshaya V. Annapragada
KBKavya Boyapati
Kavya Boyapati
DBDaniel C. Bruhm
Daniel C. Bruhm
NVNicholas A. Vulpescu
Nicholas A. Vulpescu
VVVictor E. Velculescu
Victor E. Velculescu
Liver cancer is a major cause of cancer mortality worldwide. Screening individuals at high risk, including those with cirrhosis and viral hepatitis, provides an avenue for improved survival, but current screening methods are inadequate. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome analyses to evaluate 724 individuals from the United States, the European Union, or Hong Kong with hepatocellular carcinoma (HCC) or who were at average or high-risk for HCC. Using a machine learning model that incorporated multifeature fragmentome data, the sensitivity for detecting cancer was 88% in an average-risk population at 98% specificity and 85% among high-risk individuals at 80% specificity. We validated these results in an independent population. cfDNA fragmentation changes reflected genomic and chromatin changes in liver cancer, including from transcription factor binding sites. These findings provide a biological basis for changes in cfDNA fragmentation in patients with liver cancer and provide an accessible approach for noninvasive cancer detection. Significance: There is a great need for accessible and sensitive screening approaches for HCC worldwide. We have developed an approach for examining genome-wide cfDNA fragmentation features to provide a high-performing and cost-effective approach for liver cancer detection. See related commentary Rolfo and Russo, p. 532. This article is highlighted in the In This Issue feature, p. 517

8 September 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
PTParissa Tabrizian
Parissa Tabrizian
MHMatthew L. Holzner
Matthew L. Holzner
VAVeeral Ajmera
Veeral Ajmera
AKAmy K. Kim
Amy K. Kim
KZKali Zhou
Kali Zhou
NMNeil Mehta MD
Neil Mehta MD

1 November 2018 in Translational Research
Verified
Journal Article
Closed access
YSYing-Hsiu Su
Ying-Hsiu Su
AKAmy K. Kim
Amy K. Kim
SJSurbhi Jain
Surbhi Jain

3 June 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
MHMuhammad Baraa Hammami
Muhammad Baraa Hammami
BGBrian Garibaldi
Brian Garibaldi
PSPali Shah
Pali Shah
GLGigi Y Liu
Gigi Y Liu
TJTania Jain
Tania Jain
RARobin Avery
Robin Avery
The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. We report the clinical course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory manifestations with rapid improvement after administration of off-label, single-dose tocilizumab. We also highlight the role of lung ultrasonography in early diagnosis of the inflammatory phase of COVID-19. Future investigation of the effects of immunomodulators among transplant recipients with COVID-19 infection will be important.

22 March 2019 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
AKAmy K. Kim
Amy K. Kim
FGFaiz Gani
Faiz Gani
ALAndrew J. Layman
Andrew J. Layman
SBSepideh Besharati
Sepideh Besharati
QZQingfeng Zhu
Qingfeng Zhu
RARobert Anders
Robert Anders
Fibrolamellar carcinoma (FLC) is a rare type of liver cancer that affects adolescents and young adults. The most effective treatment for FLC is surgical resection, but no standardized systemic therapy exists for patients with recurrent or unresectable FLC. As a first step to understand the immune microenvironment of FLC, we investigated targetable immune-checkpoint pathways, PD-1, PD-L1, B7-H3, IDO-1, and LAG3, in relation to CD8+ cytotoxic T-lymphocyte density. Thirty-two FLC tumor specimens were analyzed using IHC staining for PD-L1, CD8, PD-1, IDO, LAG3, and B7-H3. Sixty-three percent of FLC cases demonstrated membranous PD-L1 expression on tumor cells, and almost 70% of cases demonstrated PD-L1+ tumor-infiltrating lymphocytes and tumor-associated macrophages (TIL/TAM). Myeloid-derived cells appeared to be a major component of PD-L1+ tumor-infiltrating immune cells. Forty percent of the cases showed B7-H3 expression in the tumor zone, with 91% cases showing B7-H3 expression in TILs and TAMs. IDO and PD-1 expression was highest in the tumor interface zone. B7-H3 or IDO expression on tumor cells significantly correlated with higher CD8+ T-cell density. In conclusion, a high proportion of FLC cases showed robust expression of PD-1, PD-L1, B7-H3, and IDO in an adaptive immune-resistance pattern. Our findings provide further basis for targeting these different immune-checkpoint axes in FLC.

16 January 2025 in Hepatology Communications
Verified
Journal Article
Open access
DRDivya Rayapati
Divya Rayapati
KMKatherine McGlynn
Katherine McGlynn
JGJohn D. Groopman
John D. Groopman
AKAmy K. Kim
Amy K. Kim
The global epidemiology of HCC is shifting due to changes in both established and emerging risk factors. This transformation is marked by an emerging prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes, alongside traditional risks such as viral hepatitis (HBV and HCV), and exposure to chemical agents like aflatoxin, alcohol, tobacco, and air pollution. This review examines how environmental exposures and evolving liver pathology, exacerbated by lifestyle and metabolic conditions, are contributing to the rising worldwide incidence of HCC. Effective prevention strategies must not only address traditional risk factors through vaccination and therapeutic measures but also confront metabolic and socioeconomic disparities through comprehensive public health efforts. As the burden of liver cancer continues to grow, particularly in resource-limited settings, an expansive and inclusive approach is vital for mitigating its impact across diverse populations.